EGFR endocytosis can be a pathway from which to find novel therapeutic targets for lung cancer with wild‐type EGFR.38 An abnormality in bypass signaling pathways is another of several mechanisms of EGFR resistance to TKIs,39 and one of those bypass pathways involves vascular endothelial growth factor (VEGF) and its receptor, VEGFR. The gene discussed is KDR; the disease is lung cancer.